Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01822093Phase 1Completed

Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

Role: collaborator

NCT02095873Phase 1Completed

Healthy Aging Through Functional Food

Role: collaborator

NCT02188992Completed

Early PREdiction of Severe Sepsis I (ExPRES-Sepsis I) Study

Role: collaborator

NCT02186522Completed

Immune Failure in Critical Therapy (INFECT) Study

Role: collaborator

NCT01541852Phase 2Completed

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

Role: collaborator

NCT01929564Not ApplicableCompleted

Broccoli and Vascular Health Study

Role: collaborator

All 6 trials loaded